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Next generation sequencing (NGS)-based tumor profiling identi-
fied an overwhelming number of uncharacterized somatic muta-
tions, also known as variants of unknown significance (VUS). The
therapeutic significance of EGFR mutations outside mutational
hotspots, consisting of >50 types, in nonsmall cell lung carcinoma
(NSCLC) is largely unknown. In fact, our pan-nation screening of
NSCLC without hotspot EGFR mutations (n = 3,779) revealed that
the majority (>90%) of cases with rare EGFR mutations, account-
ing for 5.5% of the cohort subjects, did not receive EGFR-tyrosine
kinase inhibitors (TKIs) as a first-line treatment. To tackle this prob-
lem, we applied a molecular dynamics simulation-based model to
predict the sensitivity of rare EGFR mutants to EGFR-TKIs. The
model successfully predicted the diverse in vitro and in vivo sen-
sitivities of exon 20 insertion mutants, including a singleton, to
osimertinib, a third-generation EGFR-TKI (R2 = 0.72, P = 0.0037).
Additionally, our model showed a higher consistency with exper-
imentally obtained sensitivity data than other prediction ap-
proaches, indicating its robustness in analyzing complex cancer
mutations. Thus, the in silico prediction model will be a powerful
tool in precision medicine for NSCLC patients carrying rare EGFR
mutations in the clinical setting. Here, we propose an insight to
overcome mutation diversity in lung cancer.
rare EGFR mutation | mutation diversity | osimertinib | in silico prediction
model | nonsmall cell lung cancer
Recent genome-scale characterization of cancers, includingnonsmall cell lung cancer (NSCLC), revealed an extreme di-
versity of somatic gene mutations (1, 2). In the era of next gen-
eration sequencing (NGS) technologies, an overwhelming number
of novel, rare, and uncharacterized somatic mutations, classified as
variants of unknown significance (VUS), have been identified (3).
For the majority of NSCLC patients with rare mutations in on-
cogenes (i.e., VUS), appropriate precision medicine approaches
are not applicable, and therefore, their prognosis remains poor (4).
Thus, diversity of gene mutations producing VUS is an emerging
problem in oncology.
Lung cancer with epidermal growth factor receptor gene
(EGFR) mutations accounts for 10–20% and 40–50% of NSCLC
cases in Caucasians and East Asians, respectively (5). In-frame
deletions around the LREA motif of exon 19 and exon 21 L858R
point mutation, which are classic hotspot EGFR mutations, ac-
count for ∼80–90% of EGFR mutations detected in NSCLC (6),
while G719X (3% of EGFR mutations) and L861Q (2% of EGFR
mutations) are other relatively rare hotspot mutations (5, 7). All
these mutations occur in the EGFR tyrosine kinase domain and
promote the active conformation of EGFR protein, thereby con-
stitutively activating corresponding oncogenic pathways (8–10).
Multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been
approved and used in routine cancer clinics to therapeutically in-
hibit hyperactive EGFR signaling (11–16) based on the fact that a
positive relationship between the presence of these EGFR muta-
tions and sensitivity to EGFR-TKIs has been well-established (17–
19). In contrast, other EGFR mutations occurring outside hotspots
in the kinase domain are VUS, which are largely uncharacterized
due to their high diversity. EGFR exon 20 insertion mutations,
consisting of >50 types and accounting for 4–10% of all EGFR
mutations, are representatives of such VUS (7, 20, 21). Based on
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several reports that EGFR exon 20 insertion mutants are resistant
to EGFR-TKIs (7, 12, 22–24), NSCLC patients with these muta-
tions are not administered EGFR-TKIs as the first-line treatment.
However, we previously revealed that an EGFR exon 20 insertion
mutant, A763_Y764insFQEA, is sensitive to the first- and second-
generation EGFR-TKIs (23). Therefore, it is possible that a frac-
tion of patients with EGFR exon 20 insertion mutations might
benefit from therapy of some EGFR-TKIs. However, the high di-
versity of these mutations as well as the presence of many singleton
mutations prevents the comprehensive characterization of the
presently known mutants. Furthermore, the number of novel
EGFR mutations is increasing owing to the use of NGS-based tests
in lung cancer clinics. Thus, a rapid and robust method to accu-
rately predict the sensitivity of EGFR rare mutants to existing TKIs
in the clinical setting is necessary to tackle the problem that
NSCLC patients with rare EGFR mutations often lose the chance
of being treated with appropriate EGFR-TKIs.
Recently, computational structural modeling and molecular
dynamics (MD) simulations have helped us clarify the activation
mechanism of EGFR at the atomic level (25–27). In addition,
predictions of sensitivity of EGFR mutants to EGFR tyrosine
kinase inhibitors were performed for several EGFR mutations
using binding free energy calculated with MD simulation (28, 29)
and fitness scores calculated by molecular docking simulation (30).
However, there is still room for discussion on the prediction accu-
racy and robustness of these models. Also, whether these methods
can be applied to predict the sensitivity of various rare EGFR
mutants to existing TKIs at a clinically relevant level remains elusive.
We have previously developed the supercomputer-based bind-
ing free energy calculation model utilizing MD simulation (31, 32)
and applied our model to secondary ALK and RET mutants,
which appeared during therapy using TKIs (33, 34). Based on our
previous work, we hypothesized that our supercomputer-based
model would allow us to predict the sensitivity of rare EGFR
mutants to EGFR-TKIs at a clinically relevant level. To this end,
we performed an interdisciplinary study, where computer science,
cancer biology, and clinical oncology approaches were applied.
Results
High Diversity of Rare EGFR Mutations in NSCLC. To obtain clinically
relevant information regarding individual EGFR mutations and
to assess their diversity, we led the Lung Cancer Genomic
Screening Project for Individualized Medicine in Japan (LC-
SCRUM-Japan), a prospective nationwide lung cancer clinical
and genomic characterization network, in which 217 institutions
in Japan participated as of May 2017 (35). In this project,
NSCLC cases in which the major EGFR mutations (exon 19
deletions, L858R, G719X, or L861Q) were not detected by the
routine clinical testing underwent NGS evaluation for possible
somatic alterations using a panel of cancer-related genes. Within
LC-SCRUM-Japan, 3,779 NSCLC patients were enrolled from
February 2013 to March 2017. Of these patients, 201 from Oc-
tober 2013 to June 2014 (first cohort) and 1,963 from March
2015 to March 2017 (second cohort) were subjected to NGS. The
NGS study revealed that major EGFR mutations (exon 19 de-
letions, L858R, G719X, or L861Q) were detected in 2.7% (53/
1,963) of such patients in the second cohort (Fig. 1A), indicating
false negative results of routine clinical tests. Rare EGFR mu-
tations were detected in 108 (5.5%) patients. The frequency of
rare EGFR mutations was higher than those of ROS1 fusions
(3.6%) and RET fusions (2.9%). In addition, the frequency of
rare EGFR mutations comprised approximately one-third of
KRAS mutation frequency (15.3%). Rare EGFR mutations were
detected in both nonsquamous NSCLC and squamous cell carci-
noma (SI Appendix, Fig. S1). These data indicate that rare EGFR
mutations account for a significant proportion of NSCLC cases.
The distribution of rare mutations throughout the EGFR gene
sequence is illustrated in Fig. 1B. Most mutations were found in
the region encoding the tyrosine kinase domain, in exons 18–21,
while some mutations outside the tyrosine kinase domain, par-
ticularly in exons 6, 7, 8, 12, 15, and 17, were also detected. The
most frequent rare EGFR mutations were EGFR exon 20 in-
sertion mutations (Fig. 1B and SI Appendix, Table S1). Of the
113 NSCLC cases with rare EGFR mutations, including the five
cases in the first cohort and the 108 cases in the second cohort,
52 (46.0%) harbored EGFR exon 20 insertion mutations, in-
dicating that such mutations comprised about a half of rare EGFR
mutations. Of the identified 73 types of rare EGFR mutations, 68
types (93.1%) were found in only one or two cases. These data
indicate a high diversity of EGFR mutations in NSCLC.
Low Chance of EGFR-TKI Therapy for Rare EGFR Mutation Cases.
Clinical data were available for 53, 47, and 61 NSCLC patients
with EGFR major mutations (exon 19 deletions, L858R, G719X,
or L861Q), exon 20 insertion mutations, and other rare muta-
tions, respectively (SI Appendix, Table S2). Notably, the char-
acteristics of NSCLC patients with exon 20 insertion mutations
were similar to those of patients with major mutations. However,
the characteristics of NSCLC patients with other rare mutations
were slightly different by including more male and heavy smok-
ing patients. The majority of rare EGFR mutations were mutu-
ally exclusive with other driver oncogene mutations, although
coexistence with ERBB2 mutation or amplification, PIK3CA
mutation, KRAS mutation, and MET amplification was observed
in a small subset of patients (Fig. 1C). Of the 113 patients with
rare EGFR mutations, 82 patients, including 33 cases with exon
20 insertion mutations, were available for information on che-
motherapy after gene testing (Table 1 and SI Appendix, Table
S3). Of those 82 patients, 77 (93.9%) received cytotoxic che-
motherapy as first-line treatment, while only five patients (6.1%)
Fig. 1. Frequency and distribution of variants of unknown significance in
EGFR. (A) Pie chart showing the frequency of genetic alterations of indicated
genes. (B) Distribution of variants of unknown significance in the EGFR gene.
(C) Oncopanel illustrating the genetic alterations in NSCLC patients with
variants of unknown significance in EGFR.
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were treated with EGFR-TKIs as first-line treatment. Thirty-two
(97.0%) patients with EGFR exon 20 insertion mutations were
treated with cytotoxic chemotherapy as first-line treatment.
The overall response rate to EGFR-TKIs in patients with rare
EGFRmutations was only 17.4% (4/23; Table 1). Notably, one of
the four cases, who responded to afatinib, carried NSCLC with
an exon 20 insertion mutation, A767_V769dupASV (SI Appen-
dix, Table S3), and the result was consistent with our previous
study (36). This result validates that while the overall response to
first- and second-generation EGFR-TKIs for NSCLC cases with
rare EGFR mutations is low, there is a responsive subgroup
among them.
Calculation of Binding Energy of EGFR-TKIs for EGFR with Rare
Mutations. The above findings regarding EGFR mutation di-
versity and the efficacy of EGFR-TKIs for a subset of mutants
prompted us to apply our in silico drug sensitivity prediction
model (31, 32). We have previously indicated that a differential
sensitivity of two representative rare EGFR mutants, exon 20 in-
sertion mutants A763_Y764insFQEA and A767_V769dupASV,
to two EGFR-TKIs, afatinib and osimertinib, revealed that
A763_Y764insFQEA was more sensitive than A767_V769du-
pASV (36). We generated Ba/F3 cells harboring these EGFR
mutations and evaluated the sensitivity by MTS cell proliferation
assay. Here, we verified that the IC50 values of afatinib and osi-
mertinib for the EGFR mutant harboring A763_Y764insFQEA
were 10 times lower than those for the A767_V769dupASV mu-
tant (11 vs. 171 nM and 33 vs. 321 nM, respectively). First, to
evaluate whether our supercomputer-based binding free energy
(ΔGbind) calculation model could predict the difference in sensi-
tivity conferred by these mutations, we calculated ΔGbind values for
the binding of afatinib to these EGFR mutants. In this model, the
structures of EGFR molecules harboring rare mutations were built
by homology modeling, and their binding affinities for EGFR-TKIs
were evaluated using massively parallel computation of absolute
binding free energy with a well-equilibrated system (the MPCAFEE
method) (31, 32, 37). The modeled structure with bound afatinib
is shown in SI Appendix, Fig. S2A. The calculated ΔGbind
values were −23.3 and −18.5 for A763_Y764insFQEA and
A767_V769dupASV, respectively (SI Appendix, Fig. S2B), in-
dicating a more stable binding of afatinib to A763_Y764insFQEA
than to A767_V769dupASV. Although a limited efficacy of afatinib
for EGFR exon 20 insertion mutation-positive NSCLC patients was
reported (38), the potential efficacy of osimertinib for these patients
was reported (36, 39, 40), and several human clinical trials for
evaluating the efficacy of osimertinib for EGFR exon 20 insertion
mutations are ongoing. Therefore, we applied the model to osi-
mertinib and nine recurrent or novel EGFR exon 20 insertion
mutations found in our LC-SCRUM-Japan cohort including
A763_Y764insFQEA, Y764_V765insHH, A767_S768insSVD,
A767_V769dupASV, V769_D770insDNP, D770_N771insNPG,
D770_N771insNPH, N771_P772insPGD, and P772_H773insHV.
The modeled structures with bound osimertinib are shown in Fig.
2A and SI Appendix, Figs. S3 and S4. The calculated ΔGbind values
are shown in SI Appendix, Table S4. Among the variable ΔGbind
values, that of A763_Y764insFQEA was the lowest, −15.4
(kcal/mol), indicating the sensitivity of this mutation to osi-
mertinib. In contrast, although the amino acid sequence was
similar between D770_N771insNPG and D770_N771insNPH, the
calculated ΔGbind values were distinctive [−13.2 (kcal/mol) for
D770_N771insNPG and −10.0 (kcal/mol) for D770_N771insNPH].
These data may demonstrate structural complexity of osimertinib
binding to mutant EGFR proteins. Finally, we found that the
ΔGbind value for N771_P772insPGD, a mutation found in this
cohort, was the lowest [−14.3 (kcal/mol)], except for that of
A763_Y764insFQEA, among the mutations. These data indicate
the potential sensitivity of this mutation to osimertinib.
Sensitivity of EGFR with Rare Mutations to EGFR-TKIs and Its
Correlation with Calculated Binding Free Energy Values. To support
our hypothesis that the ΔGbind values of rare EGFR mutations
predict sensitivity to osimertinib, we generated a Ba/F3 library of
rare EGFR mutations that were found in the LC-SCRUM-Japan
cohort. EGFR transgenes bearing individual mutations were
transduced into Ba/F3 cells, mouse pro-B cells (23). To examine
the sensitivity of cells transduced with EGFR incorporating rare
mutations to EGFR-TKIs, we performed MTS proliferation assays.
We used the following EGFR-TKIs: erlotinib (first generation),
Table 1. Treatment response of NSCLC harboring rare EGFR mutations
Chemotherapy Mutations
Median line: 2 (range 0–8 except Exon 20 ins range 0–6)
First Second Third Fourth and more Total response rate, % (n)
Cytotoxic agent All rare mutations 77 42 27 22 —
Exon 20 ins 32 19 11 6 —
Other rares 45 23 16 16 —
EGFR-TKI
Afatinib All rare mutations 3 4 3 7 17.6 (3/17)
Exon 20 ins 1 1 1 3 16.7 (1/6)
Other rares 2 3 2 4 18.2 (2/11)
Erlotinib All rare mutations 1 1 0 1 33.3 (1/3)
Exon 20 ins 0 1 0 0 0.0 (0/1)
Other rares 1 0 0 1 50.0 (1/2)
Gefitinib All rare mutations 1 2 0 0 0.0 (0/3)
Exon 20 ins 0 0 0 0 —
Other rares 1 2 0 0 0.0 (0/3)
ICI
Nivolumab All rare mutations 0 8 8 13 3.4 (2/29)
Exon 20 ins 0 4 5 5 0.0 (0/14)
Other rares 0 4 3 8 13.3 (2/15)
Total number All rare mutations 82 57 38 43 —
Exon 20 ins 33 25 17 14 —
Other rares 49 32 21 29 —
n = 82, 33, and 49 for All rare mutations, Exon 20 ins, and Other rares, respectively. ICI, immune checkpoint
inhibitor.











afatinib (second generation), rociletinib, and osimertinib (third gen-
eration). The calculated IC50 values are shown in SI Appendix, Table
S5. Interestingly, the sensitivity data of D770_N771insNPG and
D770_N771insNPH were distinct (76 nM for D770_N771insNPG
and 427 nM for D770_N771insNPH), as predicted by binding energy
calculations. In addition, of the nine mutations examined in this
study, EGFR A763_Y764insFQEA exhibited the lowest binding
energy, indicating the most stable binding of osimertinib. The IC50
value of osimertinib in cells that expressed A763_Y764insFQEA
(33 nM) was the lowest, which matched the prediction of binding
energy calculation. Moreover, the highest IC50 value of osimertinib in
cells that expressed D770_N771insNPH (427 nM) was also predicted
by binding energy calculation. Remarkably, the ΔGbind values cal-
culated with our model showed a statistically significant correlation
(R2: 0.7232, P = 0.0037) with experimentally observed IC50 values
(Fig. 2B).
As mentioned above, to predict the sensitivity of EGFR mu-
tants to TKIs, some approaches employing the molecular dock-
ing method or MD simulation have been reported (28–30). First,
to compare the usefulness of the molecular docking method with our
model, we calculated the fitness (docking) score of TKIs to EGFR
mutants using rDock (30), which is one of the most widely used
molecular docking programs for structure-based virtual screening.
The calculated docking scores did not show a correlation with the
experimentally observed IC50 values (R
2: 0.0054, P = 0.8508; SI
Appendix, Fig. S5). The calculated docking scores using rDock are
shown in SI Appendix, Table S6. These data indicate that the mo-
lecular docking method is not useful for sensitivity prediction of
EGFR exon 20 insertion mutants.
Next, to compare the usefulness of other MD simulation-based
methods with our model, we calculated binding free energies using
MM-PBSA (Molecular Mechanics Poisson-Boltzmann Surface
Area) and MM-GBSA (Molecular Mechanics Generalized Born
Surface Area) with the MMPBSA.py module (41) in Amber
Tools, which were employed in previous studies to investigate the
sensitivity of EGFR mutants to TKIs (28, 29). Although the cal-
culated binding free energies by MM-GBSA and MM-PBSA
showed statistically significant correlations (R2: 0.5733, P =
0.018 for MM-GBSA and R2: 0.5744, P = 0.018 for MM-PBSA; SI
Appendix, Fig. S6), the correlations were lower than those of our
model. The calculated binding free energy values are shown in SI
Appendix, Table S7. These results indicate that the sensitivity of
cells expressing EGFR exon 20 insertion mutations to EGFR-
TKIs can be predicted more accurately using our in silico pre-
diction method based on MD simulation. In addition, to evaluate
the robustness of our model, we calculated the binding energies or
rDock for nonexon 20 insertion mutations to osimertinib. We
selected representative single nucleotide variations (SNVs) and
combinations of SNVs (SNV combination) mutations. The cal-
culated values are shown in SI Appendix, Tables S8 and S9. In-
terestingly, our model demonstrated higher correlations with the
experimentally observed IC50 values (R
2: 0.8392, P = 0.0288 for
SNV and R2: 0.8768, P = 0.0191 for SNV combinations) (SI Ap-
pendix, Fig. S7) than other models. These data indicate the ro-
bustness of our model for several types of EGFR mutations. In
addition, to predict the therapeutic window of each EGFR-TKI,
we have proposed that the selectivity index (SI), i.e., the ratio of
log-transformed IC50 values in Ba/F3 cells transduced with mu-
tated and wild-type EGFR, should be used (36). SI values for
EGFR-TKIs that inhibited the growth of cells with EGFR exon 20
insertions and other rare EGFR mutations are shown in SI Ap-
pendix, Figs. S8 and S9. These data indicate that osimertinib would
affect a wide spectrum of lung cancers with rare EGFRmutations.
However, sensitivity to osimertinib varied among the cells with
rare EGFRmutations as there was a >100-fold difference between
the lowest and the highest osimertinib IC50 values. These data also
indicate the variation in sensitivity of rare EGFR mutations, in-
cluding EGFR exon 20 insertion mutations to osimertinib.
Biological Confirmation of the Sensitivity of EGFR N771_P772insPGD
to Osimertinib. In this study, we have shown several previously
unreported EGFR mutations. Of these EGFR mutations, we an-
alyzed the EGFR exon 20 insertion mutation, N771_P772insPGD,
found in a 45-y-old NSCLC patient diagnosed with lung adeno-
carcinoma in 2016. The positron emission tomography-computed
tomography scan of the patient and the N771_P772insPGD se-
quences are shown in Fig. 3 A and B, respectively. Both in silico
model and experimentally obtained IC50 values predicted the
sensitivity of this mutation to osimertinib. To validate the pre-
diction that N771_P772insPGD is sensitive to osimertinib in vivo,
we generated a patient-derived xenograft (PDX) model from
pleural effusion of this patient. The histology of the PDX tumor in
the mouse was also confirmed as adenocarcinoma (SI Appendix,
Fig. S10). Consistent with the in silico prediction results, once-
daily administration of 25 mg/kg (a dose that approximates the
clinically approved 80-mg dose; ref. 39) or 50 mg/kg osimertinib
induced a significant regression of the tumor (Fig. 3C and SI
Appendix, Fig. S11). These data indicate that osimertinib could be
effective in NSCLC cases with this mutation. These data support
the applicability of the in silico prediction model for predicting the
sensitivity of NSCLC with rare EGFR mutations to EGFR-TKIs.
Fig. 2. Calculation of binding energy values for EGFR exon 20 insertion muta-
tions. (A) Structures ofmutated EGFR kinase domains for EGFRA763_Y764insFQEA,
A767_V769dupASV, D770_N771insNPG, and N771_P772insPGD were modeled us-
ing wild-type EGFR data (Protein Data Bank ID code 4ZAU). The structures
were extracted from the trajectories of 50-ns molecular dynamics simula-
tions that were used for binding affinity calculations. The structures in gray
and in colors are wild-type and mutated EGFRs, respectively. Mutated amino
acids in EGFR structures are indicated in red. Osimertinib molecules are shown as
sticks (white, carbon; blue, nitrogen; red, oxygen). (B) Plot of ΔGbind values
against negative log-transformed IC50 values. Each mutated EGFR is indicated by
a dot. Dashed line represents a linear fit with squared correlation coefficient R2.
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Discussion
In this study, we clarified the diversity and driver roles of rare
EGFR mutations in a large prospective Japanese NSCLC cohort
and revealed the limited efficacy of precision medicine approaches
for NSCLC patients with rare EGFR mutations. Among the 73
types of rare EGFR mutations detected, 68 (93.1%) were found in
only one or two patients; the frequency of each rare EGFR mu-
tation was less than 0.1%. In addition, sensitivity to EGFR-TKIs
was quite diverse even if the mutation sequences were similar, e.g.,
for EGFR with D770_N771insNPG and D770_N771insNPH
mutations. These data point to the diversity of rare EGFR mu-
tations in their structural interaction with EGFR-TKIs. In vitro
and/or in vivo experimental evaluation of drug sensitivity is ef-
fective in the evaluation of a few EGFR exon 20 mutants as shown
by recent studies (42, 43). However, considering the extremely low
frequency of each mutation and the continual appearance of novel
mutations, such methods are not realistic in the clinical setting.
To overcome the problem of such mutation diversity, we, here,
applied a supercomputer-based in silico prediction model that can be
used to promptly estimate sensitivity to existing TKIs, obviating the
need for time-consuming “wet” experiments. In this model, ΔGbind
values that are highly correlated with sensitivity to drugs can be
obtained in approximately 1 wk. Although several reports have
proposed the availability of the in silico approach, by employing MD
simulation, for predicting drug sensitivity of several EGFRmutations
(28, 29), our model demonstrated the highest prediction accuracy
based on comparisons with experimentally obtained sensitivity values.
These results indicate the usefulness and robustness of our model
and show the potential to overcome mutation diversity in cancer.
Here, in this study, we evaluated our model based on experi-
mentally observed values for binding affinity. Since osimertinib is
one of the targeted covalent inhibitors, further discussion on both
the binding affinity and the rate of the subsequent bond-forming
reaction will be needed. Of course, the clinical utility of our
method should be evaluated in humans since it has been evaluated
only in the PDX model. In this study, we indicated the efficacy of
osimertinib for several EGFR exon 20 mutants. Thus, we have
launched a clinical trial to evaluate the efficacy of osimertinib for
cases with EGFR exon 20 insertion mutations [University Hospital
Medical Information Network (UMIN) 000031929]. Prospective
in silico and in vivo studies of these patients will prove the utility of
our prediction method. Recent large-scale genomic characteriza-
tion programs as well as rapid technological advancements have
enabled the application of NGS in the clinical setting to identify
numerous mutations in a variety of genes in lung and other can-
cers. Nonhot spot EGFR mutations have been discovered in small
fractions of several cancers other than NSCLC. Application of our
method might improve the prognosis of cancer patients by guiding
drug development or promoting drug repositioning based on in-
formation on VUS in cancers.
Methods
Patients. LC-SCRUM-Japan is a prospective, nationwide clinical and genomic
screen of lung cancer (UMIN ID: UMIN000010234). In this study, a total of
3,779 NSCLC patients were enrolled from February 2013 to March 2017.
Cases with NSCLC stage II or more advanced stage [tumor, nodes, metastasis
(TNM) classification version 7], which were confirmed to have no major EGFR
mutations (exon 19 deletions, L858R, G719X, or L861Q) by local hospitals, were
included. The methods of EGFR mutation detection performed in local hos-
pitals included PNA-LNA PCR clamp, Scorpion-ARMS, Cyclerve PCR, PCR-
invader, or Cobas EGFR mutation assay v.2. All patients provided written in-
formed consent for the entry to the LC-SCRUM-Japan study.
DNA Extraction and Next Generation Sequencing. In this study, DNA samples
were extracted from fresh frozen specimens or pleural effusion. From Oc-
tober 2013 to June 2014 (first cohort), DNA samples from 201 cases were
analyzed by a targeted NGS assay, the Ion Ampliseq Cancer Hotspot Panel
(Thermo Fisher Scientific). From March 2015 to March 2017 (second cohort),
DNA samples from 1,963 cases were analyzed by another targeted NGS assay,
the Oncomine Comprehensive Assay (OCA v.1) (Thermo Fisher Scientific).
Sequencing of the paired normal tissues or blood was not performed in this
cohort. We selected potential somatic mutations those are registered as
“confirmed somatic” in the COSMIC (Catalogue Of Somatic Mutations In
Cancer) database. The mutations confirmed as somatic mutations by the
COSMIC database are indicated with * in SI Appendix, Table S1. The present
study was approved by the institutional Ethics Committee of all 217 insti-
tutions (SI Appendix, Table S10) that participated in the LC-SCRUM-Japan
cohort. All patients provided written informed consent for the molecular
analysis of their samples. All analyses were done at SRL, Inc.
Statistical Analysis. IBM SPSS Statistics 24 was used for data management and
statistical analyses. For descriptive analysis, quantitative variables are expressed
as the median and range. Categorical variables are expressed as the number of
cases and percentage. Two-sided Student’s t tests were used for pairwise
comparisons. The Pearson’s correlation test was performed to calculate R and P
values. All statistical analyses were conducted with a significance level of
α = 0.05 (P < 0.05). All P values are two-sided.
Other methods are described in SI Appendix.
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